EUVIMEDEUVIMED entdecken
Crossref

L26/P-542 Low-molecular-weight heparin improves implantation after single euploid or low-level mosaic blastocyst transfer following PGT-A

J.H. Lee, J.Y.P. Ho, W.F. Chang, S.J. Tan, R.S. Wang, H. Huang, Y.E. Chang, Y.X. Lee, Y.M. Hu, C.R. Tzeng

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.875 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von J.H. Lee und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does Low-molecular-weight heparin (LMWH) improve pregnancy outcomes after single blastocyst transfer following PGT-A, and does its effect vary by prior-failed transfer history? Summary answer LMWH improves early implantation after PGT-A single blastocyst transfer, especially in prior-failed transfers, but miscarriage remains high, suggesting additional strategies are needed to maintain pregnancy. What is known already LMWH has been proposed as an adjuvant therapy in assisted reproductive technology due to its anticoagulant, anti-inflammatory, and potential endometrial receptivity–modulating effects. Its use has been explored mainly in patients with recurrent implantation failure or thrombophilia, with inconsistent results and no recommendation for routine use. In PGT-A cycles, where embryo chromosomal competence is optimized, implantation failure may reflect endometrial or immunological factors. Evidence evaluating LMWH specifically in PGT-A cycles, particularly stratified by prior PGT-A transfer failure, remains limited. Study design, size, duration This single-center retrospective cohort study included 2,502 cycles of single euploid or low-level mosaic blastocyst transfer following PGT-A performed between March 2020 and November 2025. A predefined subgroup analysis was performed in patients with a history of failed blastocyst transfer following PGT-A (n = 359). The study was approved by the Institutional Review Board of Tri-Service General Hospital, Taipei, Taiwan (No. B202505136). Participants/materials, setting, methods All autologous IVF–PGT-A cycles with single euploid or low-level mosaic blastocyst transfer were included. Cycles were stratified by LMWH use, administered per physician judgment, and prior failed transfer history. Outcomes were compared using chi-square and t tests. Multivariable logistic regression was used to assess predictors of implantation, defined as ultrasound visualization of a gestational sac, adjusting for maternal age, AMH, BMI, embryo grade, day of blastocyst development, and LMWH use. Main results and the role of chance In the overall cohort (n = 2,502), LMWH administration was associated with significantly higher rates of positive serum β-hCG, gestational sac visualization, fetal heartbeat detection, and ongoing pregnancy compared with cycles without LMWH use (all p < 0.001). After adjustment for relevant clinical and embryological covariates, LMWH use remained independently associated with implantation (adjusted odds ratio [aOR] 1.58, 95% confidence interval [CI] 1.26–1.99, p < 0.001) and ongoing pregnancy (aOR 1.44, p = 0.001). In patients with a history of failed PGT-A single blastocyst transfer (n = 359), prior failed transfer was independently associated with reduced implantation probability. However, LMWH use was independently associated with a higher likelihood of implantation (aOR 2.19, 95% CI 1.05–4.55, p = 0.036). Despite improved implantation, miscarriage rates were higher in LMWH-treated cycles, indicating that LMWH may facilitate early implantation but does not sufficiently improve post-implantation pregnancy maintenance. Limitations, reasons for caution The retrospective design limits causal inference, and residual confounding cannot be excluded. LMWH dosage, timing, and duration were not standardized, and thrombophilia or immunological status was not systematically assessed. As a single-center study, prior implantation failure was identified only within the institution and not comprehensively assessed, which may limit generalizability. Wider implications of the findings LMWH may enhance implantation efficiency in PGT-A single blastocyst transfer cycles, particularly among patients with previous failed PGT-A transfers. However, its limited impact on pregnancy and higher miscarriage rates suggest that LMWH should not be routinely used and highlight the need for careful patient selection and complementary post-implantation strategies. Trial registration number No

Zitieren

APA

Lee, J., Ho, J., Chang, W., Tan, S., Wang, R., Huang, H., Chang, Y., Lee, Y., Hu, Y., & Tzeng, C. (2026). L26/P-542 Low-molecular-weight heparin improves implantation after single euploid or low-level mosaic blastocyst transfer following PGT-A. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.875

Vancouver

Lee J, Ho J, Chang W, Tan S, Wang R, Huang H, et al. L26/P-542 Low-molecular-weight heparin improves implantation after single euploid or low-level mosaic blastocyst transfer following PGT-A. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.875

BibTeX
@article{Lee2026,
  author = {Lee, J.H. and Ho, J.Y.P. and Chang, W.F. and Tan, S.J. and Wang, R.S. and Huang, H. and Chang, Y.E. and Lee, Y.X. and Hu, Y.M. and Tzeng, C.R.},
  title = {L26/P-542 Low-molecular-weight heparin improves implantation after single euploid or low-level mosaic blastocyst transfer following PGT-A},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.875}
}
Kostenlos starten →